Search | IOVS | ARVO Journals

Showing 1 – 20 of 56

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

A gene-agnostic treatment for diseases caused by nonsense mutation.

Bikash R Pattnaik; Meha Kabra; Lionel Gissot; Divya Sinha; David M Gamm; Christopher A Ahern

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):2478.

ARVO Annual Meeting Abstract June 2025

Identification, structural and functional characterization of a novel Cacna1f mutation associated with X-linked recessive CSNB

Sanjai Kumar Pillala; Pawan K Shahi; BIKASH Ranjan PATTNAIK

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):2356.

ARVO Annual Meeting Abstract June 2024

CRISPR VISION Program: Nonviral Genome Editing to Treat Congenital Blindness

Bikash R Pattnaik; Krishanu Saha; David M Gamm; Shaoqin Sarah Saha; T Michael Nork; William L Murphy; Rina Mepani; Mary HaakFrendscho

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4266.

ARVO Annual Meeting Abstract June 2024

Engineered tRNA to overcome nonsense mutation for the rescue of Kir7.1 physiological function

Enes AKYUZ; Pawan Shahi; Divya Sinha; Giovanni M. Hanstad; Lionel Gissot; Ahmad Al Saneh; David M Gamm; Christopher A Ahern; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6092.

ARVO Annual Meeting Abstract June 2024

eRNPs, a programmable ribonucleoprotein, edits the retinal pigment epithelial cells

Pawan Shahi; Rina Mepani; Aaron J Cantor; Mary Janatpour; Mary HaakFrendscho; Krishanu Saha; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6087.

ARVO Annual Meeting Abstract June 2023

Characterization of KCNQ sub-types in the mouse retinal neurons

Sehrish Afsheen; Pawan K Shahi; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4739.

ARVO Annual Meeting Abstract June 2023

Strategies for Readthrough of Premature Termination Codons to Restore Ion Channel Function

Stephen Fulbright; Meha Kabra; Pawan K Shahi; Allison Spillane; Christopher Ahern; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):414.

ARVO Annual Meeting Abstract June 2023

A mouse model of human Congenital Stationary Night Blindness (CSNB) for therapeutic evaluation

Bikash R Pattnaik; Pawan K Shahi; Meha Kabra

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):412.

ARVO Annual Meeting Abstract June 2022

Transmembrane protein 135 regulates lipid metabolism in mouse eyecup

Akihiro Ikeda; Michael Landowski; Vijesh Bhute; Tetsuya Takimoto; Samuel Grindel; Pawan K Shahi; Bikash R Pattnaik; Sakae Ikeda

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):872.

ARVO Annual Meeting Abstract June 2022

A novel Kcnv2 nonsense mutation mouse model of Cone Dystrophy with Supernormal Rod Response

Pawan K Shahi; Aniruddh Srinivasan; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1784 – F0333.

ARVO Annual Meeting Abstract June 2022

KCNQ-targeting drugs reveal a possible regulatory role in visual light response

Aniruddh Srinivasan; Pawan K Shahi; Sehrish Afsheen; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2497 – F0204.

ARVO Annual Meeting Abstract June 2022

Functional restoration of Kir7.1 nonsense mutations using engineered tRNA

Bikash R Pattnaik; Meha Kabra; Pawan K Shahi; Enes Akyuz; Christopher Ahern

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3847.

ARVO Annual Meeting Abstract June 2022

Wearable Light Isolating Medical Device to Perform Electroretinography

Colin Korlesky; James N Ver Hoeve; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):744 – F0396.

ARVO Annual Meeting Abstract June 2021

Preclinical Testing of HUB-101, a Potential Gene Therapy for LCA16

Allison Spillane; Katie Beverley; Pawan K Shahi; Susan Macdonald; Sarah M Hall; Jeff Sabados; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2601.

ARVO Annual Meeting Abstract June 2021

CRISPR base editing as a potential therapeutic approach for Kir7.1 channelopathy

Meha Kabra; Pawan K Shahi; ALLISON SPILLANE; Yuyuan Wang; Divya Sinha; Gregory A Newby; Shivani Saxena; Krishanu Saha; Mariya Moosajee; David Gamm; David R. Liu; Shaoqin Gong; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1483.

ARVO Annual Meeting Abstract June 2021

The Quest for a Safer Alternative to Viral Gene Therapy Continues

Pawan K Shahi; Meha Kabra; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1470.

ARVO Annual Meeting Abstract June 2021

Translational Read-through of a KCNJ13 nonsense mutation with ELX-01 and ELX-03 results in functional Kir7.1 channels

HENRY ZAPATA GALARZA; Pawan K Shahi; Doug W. McMillin; Daniel K. Crawford; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):209.

Retinal Cell Biology October 2020

Modulation of Tmem135 Leads to Retinal Pigmented Epithelium Pathologies in Mice

PDF

Michael Landowski; Samuel Grindel; Pawan K. Shahi; Abigail Johnson; Daniel Western; Adrienne Race; Franky Shi; Jonathan Benson; Marvin Gao; Evelyn Santoirre; Wei-Hua Lee; Sakae Ikeda; Bikash R. Pattnaik; Akihiro Ikeda

Invest. Ophthalmol. Vis. Sci.. 2020; 61(12):16. https://doi.org/10.1167/iovs.61.12.16

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Primary congenital glaucoma-associated truncation of GJA1 modeled in mice

Sean Michael Martin; Kristina Whisenhunt; Stuart William Tompson; Pawan Shahi; Sarah M LaMartina; Andrea Moyer; Bikash R Pattnaik; Leandro Teixeira; Terri L Young

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1257.

ARVO Annual Meeting Abstract June 2020

CRISPR Base Editing; A feasible treatment for inherited retinopathy

Meha Kabra; Allison Spillane; Pawan Shahi; David M Gamm; Amr A Abdeen; Krishanu Saha; Bikash R Pattnaik

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2451.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

A gene-agnostic treatment for diseases caused by nonsense mutation.

Identification, structural and functional characterization of a novel Cacna1f mutation associated with X-linked recessive CSNB

CRISPR VISION Program: Nonviral Genome Editing to Treat Congenital Blindness

Engineered tRNA to overcome nonsense mutation for the rescue of Kir7.1 physiological function

eRNPs, a programmable ribonucleoprotein, edits the retinal pigment epithelial cells

Characterization of KCNQ sub-types in the mouse retinal neurons

Strategies for Readthrough of Premature Termination Codons to Restore Ion Channel Function

A mouse model of human Congenital Stationary Night Blindness (CSNB) for therapeutic evaluation

Transmembrane protein 135 regulates lipid metabolism in mouse eyecup

A novel Kcnv2 nonsense mutation mouse model of Cone Dystrophy with Supernormal Rod Response

KCNQ-targeting drugs reveal a possible regulatory role in visual light response

Functional restoration of Kir7.1 nonsense mutations using engineered tRNA

Wearable Light Isolating Medical Device to Perform Electroretinography

Preclinical Testing of HUB-101, a Potential Gene Therapy for LCA16

CRISPR base editing as a potential therapeutic approach for Kir7.1 channelopathy

The Quest for a Safer Alternative to Viral Gene Therapy Continues

Translational Read-through of a KCNJ13 nonsense mutation with ELX-01 and ELX-03 results in functional Kir7.1 channels

Modulation of Tmem135 Leads to Retinal Pigmented Epithelium Pathologies in Mice

Primary congenital glaucoma-associated truncation of GJA1 modeled in mice

CRISPR Base Editing; A feasible treatment for inherited retinopathy

To View More...

You must be signed into an individual account to use this feature.